Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SCIENTIFIC LETTER

Transient drop in the neutrophil count during COVID-19 regardless of clozapine treatment in patients with mental illness

Disminución transitoria del recuento de neutrófilos durante COVID-19 independiente del tratamiento con clozapina en pacientes con esquizofrenia

Research letter

People with mental health disorders are at increased risk for coronavirus disease 2019 (COVID-19) and its severe complications, including a high mortality rates, compared to the general population. In addition, the high prevalence of medical comorbidities in this population make the COVID-19 treatment more challenging and potentially less effective.

In this sense, the use of clozapine, an atypical antipsychotic medication indicated for treatment-refractory schizophrenia has been associated to an increased susceptibility to COVID-19 infection compared with other antipsychotic medications. Moreover, prescribing clozapine requires close monitoring for serious adverse events, including agranulocytosis, myocarditis, aspiration pneumonia, and clozapine toxicity, as seizures, ileus and delirium, which could be higher in the setting of COVID-19, as clozapine plasma concentrations increase during acute systemic infection because of the CYP1A2 enzymes' inhibition by cytokines, and the reduction or ceasing tobacco smoking in patients during acute illness.

Owing to the risk of clozapine-associated severe neutropenia, absolute neutrophil count monitoring programs are a prerequisite for clozapine dispensation. Clozapine neutropenia appears usually in the first 18 weeks of treatment with progression to life-threatening agranulocytosis in a minority of patients (0.8%). However, during COVID-19 pandemic, some case series have reported a reduction in neutrophil count and severe neutropenia in patients on clozapine treatment, resulting in clozapine withdrawal, and raising the concern of clozapine toxicity in the setting of COVID-19. Nevertheless, these studies were case series and did not have a group control of patients without clozapine treatment to evaluate the effects of the medication or the infection on the neutrophil counts.

Therefore, the aims of study was to compare the neutrophil dynamics during COVID-19 between patients with mental illness according to the clozapine use.

This observational study was conducted at the Emili Mira Healthcare Center, a public acute and long-term psychiatric care center in Barcelona (Spain) with 300 places and dependent on a large tertiary teaching hospital.

People with mental illness on the basis of ICD-10, who had a positive determination of coronavirus SARS-CoV-2 real time reverse-transcription-polymerase chain reaction (cobas® SARS-CoV-2 Test Roche laboratories) in nasopharyngeal samples were included in the study. Patients with lack of data on hematological parameters during COVID-19 or suffering from hematological malignancies or immunodeficient states (excluding diabetes mellitus) or less than six months on stable psychiatric treatment were excluded from the study. Patients were identified from the database of the patients admitted in the center from March 2020 to February 2021.

For the purpose of the study, socio-demographic and clinical characteristics were extracted from the patients' medical records and categorized to maintain anonymity where necessary.

The total leukocytes count, absolute neutrophil count and lymphocyte count were the registered hematological parameters. Baseline counts were considered those taken at least 30 days before a positive SARS-CoV-2 test; COVID-19 counts, those taken between the day of the positive SARS-CoV-2 test and seven days later; and post-COVID-19 count, those counts taken between seven and fourteen days before of positive SARS-CoV-2 test. Psychiatric polypharmacy was defined as the prescription of two or more psychiatric medications concurrently to a patient.

The main outcome of the study was the change of the neutrophil count during COVID-19, measured as the total difference between the baseline and COVID-19 count. The secondary objectives were the incidence of neutropenia, measured as a neutrophil count <1500 cells/mcl and the change of neutrophil count during COVID-19 according to the use of clozapine treatment.

Descriptive statistics were expressed as median and interquartile range for quantitative variables and absolute frequencies and percentages for qualitative variables. Wilcoxon test was used to compare quantitative variables. Analysis were made using SPSS software, version 17.0.0 (Chicago, IL).

The study complied with the ethical statements in the Declaration of Helsinki (64th General Assembly, Fortaleza, Brazil, October 2013) and was approved by the local Institutional Review Board.
There were 69 patients admitted in the center who had COVID-19 during the study period. Thirty-eight patients were excluded for lack of hematological parameters. Finally, a total of 31 patients were included in the study.

Clinical characteristics of the patients are shown in Table 1. All patients had schizophrenia spectrum disorders, psychiatric polypharmacy and were on second-generation antipsychotic treatment. The main medical comorbidities were: obesity in 17 (54.8%) patients, hypertension in 11 (26.8%), chronic respiratory diseases in 8 (25.8%), diabetes in 6 (19.3%), chronic heart diseases in 3 (9.6%), and chronic kidney diseases in 3 (9.6%).

Three quarter of patients had mild COVID-19 and two patients died.

Half of patients were on clozapine treatment with a median clozapine doses of 350 (IQR: 175–400) mg/day and baseline plasma concentration of 450 (IQR: 370–490) ng/mL. Median plasma concentrations at COVID-19 (available for 12 patients) were 604 (400–870) ng/mL and statistically significant (p = 0.04) compared to baseline levels. Five patients had clozapine levels >600 ng/mL requiring dose reduction.

Median blood parameters by time period are shown in Fig. 1. A significant decrease of total leukocytes (4510 cells/mL), absolute neutrophils (3000 cells/mL) and lymphocytes (1280 cells/mL) were observed at COVID-19 compared to baseline (p < 0.01 for all comparisons). A significant increase of total leukocytes (7200 cells/mL, p = 0.01), absolute neutrophils (4150 cells/mL, p = 0.01) and lymphocytes (1705 cells/mL, p = 0.03) at post-COVID-19 were observed compared to COVID-19 counts. There was not statistically significant differences between total leukocytes (p = 0.85), absolute neutrophil (p = 0.81) counts between baseline and post-COVID-19 counts, while lymphocyte was significant (p = 0.05).

Median change of neutrophil count at COVID-19 was -560 cells/mL (IQR: -1510, -1160) representing a median percentage of -27.6% (IQR: -47%, -2%). There was not differences in median neutrophil change according to clozapine use; -680 (IQR: -1502, -145) cells/mL for the clozapine group and -550 (IQR: -1805, -405) cells/mL for the non-clozapine group (p = 0.51).

Clinical characteristics of the three patients with neutropenia are shown in Table 2. Two patients received clozapine treatment and had previous neutropenia during clozapine titration. Clozapine treatment was temporarily discontinued in one of them for decreasing neutrophil count to 100 cells/mL. After withdrawal of new medication introduced for the COVID-19 treatment, neutropenia was resolved.

The results observed in this study showed that during COVID-19 there was a transient drop fall in the neutrophil count in patients with mental illness, regardless of the type of second-generation antipsychotic treatment they received. In addition, cases of neutropenia were related to the introduction of new medications for the COVID-19 treatment.

Viral infections, including those caused by Epstein–Barr virus, cytomegalovirus, hepatitis A and B viruses, parvovirus, influenza virus species, measles and HIV, are a common cause of neutropenia, due either to bone marrow suppression or to peripheral destruction. In the case of COVID-19, lymphopenia followed by thrombopenia are the most usual hematological findings. However, alterations in neutrophils have also been reported and associated to the severity and progression of the disease; while a small fall of neutrophil counts has been observed in mild cases, an increased in neutrophil counts together a decrease in lymphocyte count has been considered a risk factor for Acute Respiratory Distress Syndrome during the disease course.

Thus, the transitory neutrophil count drop observed in this study, which included mostly non-severe COVID-19 cases, is according to data observed in mild COVID-19 cases. This finding have several major implications. First, clozapine should generally be continued...
as the neutrophil count decrease seems to be a non-pathological event during mild COVID-19. However, close plasma concentration monitoring is advisable, as clozapine plasma concentrations increased during COVID-19 in this study, resulting in dose readjustment in five patients. The CYP1A2 enzymes’ inhibition by cytokines released during an infection and the reduction or ceasing tobacco smoking in patients during acute illness are well established risk factors that can increase clozapine plasma concentrations during COVID-19.

Second, patients who experience neutropenia in the course of COVID-19 should be investigated and monitored as per routine clinical practice, as it cannot be assumed to be secondary to the viral infection or clozapine treatment. Nevertheless, other causes of drug-induced neutropenia should be evaluated, particularly medications used for the treatment of infection. In addition, it is interesting to note that the two patients with neutropenia had the antecedent of previous neutropenia during clozapine titration and a low baseline neutrophil, which could be used as a marker of future risk of neutropenia.

Finally, it is important to evaluate the risk of drug-drug interactions of COVID-19 treatments to prevent the risk of clozapine toxicity; as some antiretrovirals, as lopinavir and darunavir, which were widely used during the first months of the pandemic without clinical efficacy against coronavirus SARS-CoV-2, are inhibitors of the cytochrome P450.

The study had some limitations, namely the observational design and the small number of patients included. However, patient’s clinical characteristics were well defined, including a stable antipsychotic treatment. These results should be confirmed in larger samples.

In conclusion, this study showed the relevance of a comprehensive clinical assessment of suspected COVID-19 infection in patients with mental illness, including evaluation for features of pneumonia, full blood count and risk of side effects of newly introduced treatments. In addition, clozapine treatment should be continued at least in mild cases, however, consideration should be given to dose reduction.

### Table 2  Clinical characteristics of the three patients with neutropenia.

| Patient | 1 | 2 | 3 |
|---------|---|---|---|
| **Age (years)** | 57 | 55 | 68 |
| **Sex** | Woman | Woman | Man |
| **Psychiatric diagnosis** | Schizophrenia | Schizophrenia | Schizophrenia |
| **Clozapine use** | Yes | Yes | No |
| Baseline levels (ng/mL) | 454 | 378 | – |
| COVID-19 levels (ng/mL) | 850 | 587 | – |
| Severity COVID-19 | Mild | Moderate | Mild |
| **Neutrophil count(cell/μL)** | | | |
| Baseline | 2390 | 2130 | 4500 |
| COVID-19 | 970 | 100 | 1300 |
| Post-COVID-19 | 1850 | 3150 | 5380 |
| **Cause** | Hydroxychloroquine | Metamizol | Ibuprophene |

### References

1. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorders: retrospective cohort studies of 62,354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130–40.
2. Lee SW, Yang JM, Moon SY, Yoo IK, Ha EK, Kim SY, et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 2020;7:1025–31.
3. Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021;20:124–30.
4. Li L, Li F, Fortunati F, Krystal JH. Association of a prior psychiatric diagnosis with mortality among hospitalized patients with Coronavirus Disease 2019 (COVID-19) infection. JAMA Netw Open. 2020;3:e2023282, http://dx.doi.org/10.1001/jamanetworkopen.2020.23282.
5. Nemani K, Li C, Olfson M, Blessing EM, Razavian N, Chen J, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. 2021;7:204442, http://dx.doi.org/10.1001/jamapsychiatry.2020.4442.
6. Šimunović Filipčić I, Filipčić I. Schizophrenia and physical comorbidity. Psychiatr Danub. 2018;30 Suppl. 4:152–7.
7. Nandy K, Salunke A, Pathak SK, Pandey A, Doctor C, Puj K, et al. Coronavirus disease (COVID-19): a systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. Diabetes Metab Syndr. 2020;14:1017–25.
8. Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: a systematic review. Diabetes Metab Syndr. 2020;14:1133–42.
9. Siskind D, McCartney L, Goldschlag R, Kisyel S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209:385–92.
10. Govind R, Fonseca de Freitas D, Pritchard M, Hayes RD, McCabe JH. Clozapine treatment and risk of COVID-19 infection: retrospective cohort study. Br J Psychiatry. 2020;27:1–7.
11. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry. 2000;61 Suppl. 8:14–7.
12. Iqbal E, Govind R, Romero A, Dzahini O, Broadbent M, Stewart R, et al. The side effect profile of Clozapine in real
world data of three large mental health hospitals. PLOS ONE. 2020;15:e0243437.
13. Clark SR, Warren NS, Kim G, Jankowiak D, Schubert KO, Kisely S, et al. Elevated clozapine levels associated with infection: a systematic review. Schizophr Res. 2018;192:50–6.
14. Wagner E, McMahon L, Falkai P, Hasan A, Siskind D. Impact of smoking behavior on clozapine blood levels – a systematic review and meta-analysis. Acta Psychiatr Scand. 2020;142:456-66.
15. Cranshaw T, Harikumar T. COVID-19 infection may cause clozapine intoxication: case report and discussion. Schizophr Bull. 2020;46:751.
16. Dotson S, Hartvigsen N, Wesner T, Carbay TJJ, Frichchione G, Freudenberg O. Clozapine toxicity in the setting of COVID-19. Psychosomatics. 2020;61:577–8.
17. Bonaccorso S, Ricciardi A, Ouabou S, Teleritis C, Ross-Michealides A, Metastasio A, et al. Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months report. Brain Behav Immun Health. 2021;13:100212.
18. Gee S, Taylor D. COVID-19 infection causes a reduction in neutrophil counts in patients taking clozapine. J Psychiatry Neurosci. 2021;46:E232–7.
19. Butler M, Bano F, Calcia M, McMullen I, Sin Fai Lam CC, Smith LJ, et al. Clozapine prescribing in COVID-19 positive medical inpatients: a case series. Ther Adv Psychopharmacol. 2020;10, 2045125320959560.
20. Siskind D, Honer WG, Clark S, Correll CU, Hasan A, Howes O, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020;45:200061.
21. Gee S, Gaughran F, MacCabe J, Shergill S, Whiskey E, Taylor D. Management of clozapine treatment during the COVID-19 pandemic. Ther Adv Psychopharmacol. 2020;10, 2045125320928167.
22. Singh N, Singh Lubana S, Dabrowski L. Isolated chronic and transient neutropenia. Cureus. 2019;11:e5616, http://dx.doi.org/10.7759/cureus.5616.
23. Galani IE, Andreakos E. Neutrophils in viral infections: current concepts and caveats. J Leukoc Biol. 2015;98:557–64.
24. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95:834–47.
25. Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol. 2020;42 Suppl. 1:11–8.
26. Zladi A, Hachimi A, Admou B, Hazez R, Brahim I, Dourek F, et al. Lymphopenia in critically ill COVID-19 patients: a predictor factor of severity and mortality. Int J Lab Hematol. 2021;43:e38–40.
27. Lin S, Mao W, Zou Q, Lu S, Zheng S. Associations between hematological parameters and disease severity in patients with SARS-CoV-2 infection. J Clin Lab Anal. 2021;35:e23604.
28. Anurag A, Jha PK, Kumar A. Differential white blood cell count in the COVID-19: a cross-sectional study of 148 patients. Diabetes Metab Syndr. 2020;14:2099–102.
29. Palmblad J, Nilsson CC, Höglund P, Papadaki HA. How we diagnose and treat neutropenia in adults. Expert Rev Hematol. 2016;9:479–87.
30. Curtis BR. Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am Soc Hematol Educ Program. 2017;2017:187–93.

Gabriel Vallecillo a,b,c, Josep Marti-Bonany a, Maria José Robles c, Joan Ramón Fortuny a, Fernando Lana b, Victor Pérez a,d

a Psychiatry Department, Emili Mira Healthcare Center, Parc de Salut Mar Consortium, Barcelona, Spain
b Addiction Research Group, Institut Hospital del Mar d'Investigacions Mèdiques, Parc de Salut Mar, Barcelona, Spain
c Geriatric Department Parc de Salut Mar, Consortium, Barcelona, Spain
d Mental Health Research Group, Institut Hospital del Mar d’Investigacions Mèdiques, Parc de Salut Mar, Barcelona, Spain

*Corresponding author.
E-mail address: 91773@psmar.cat (G. Vallecillo).
https://doi.org/10.1016/j.rpsm.2021.06.002 1888-9891/ © 2021 SEP y SEPB. Published by Elsevier España, S.L.U. All rights reserved.

ECT: A decision to decrease risks during COVID-19 pandemic
TEC: una decisión para disminuir riesgos durante la pandemia COVID-19

Introduction

Electroconvulsive therapy (ECT) is a highly effective treatment for severe psychopharmacological resistant patients but it is also a procedure that involves open airway management and has been considered as an aerosol generating procedure. The COVID-19 pandemic, has resulted in reductions in ECT services internationally. The COVID-19 pandemic has dramatically and rapidly transformed hospitals in heavily affected areas, decreasing mental health services. The need to locate critical patients in spaces intended for anesthesia, as the post-anesthesia care unit (PACU) where we usually administered ECT, has forced us to decrease the number of procedures and be highly selective. In the same way, continuation and maintenance ECT (m-ECT) have also been dramatically reduced.

Recently it has been recommended to consider for ECT only those asymptomatic for COVID-19 disease, and test each patient for SARS-CoV-2 virus close to the time of their procedure, not allowing to proceed with ECT to SARS-CoV-2-positive patients. Modified Anesthesia Protocol for ECT was not offered to patients known or suspected to be positive for the virus. Lapid et al. state that ECT is an essential treatment that should continue to be provided even during this pandemic. If a known COVID-19 positive patient, whether symptomatic or not, needs ECT as life-saving procedure for a life-threatening condition, it should be administered in an operating room (OR) set-up with negative pressure.

Here we report two cases of psychopharmacological refractory patients that were treated with ECT despite having proven positive for COVID-19 disease. We decided to